Chang-Ching Lin

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Breast Cancer Cells

Endoplasmic Reticulum

Top Venues

Nature communications

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Kyung-Min Lee, Chang-Ching Lin, Alberto Servetto, Joonbeom Bae, Vishal Kandagatla, Dan Ye, Gun Min Kim, Dhivya R Sudhan, Saurabh Mendiratta, Paula I Gonzalez Ericsson, Justin M Balko, Jeon Lee, Spencer Barnes, Venkat S Malladi, Siamak Tabrizi, Sangeetha M Reddy, Seoyun Yum, Ching-Wei Chang, Katherine E Hutchinson, Susan E Yost, Yuan Yuan, Zhijian J Chen, Yang-Xin Fu, Ariella B Hanker, Carlos L Arteaga
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer immunology research 10 (7) (2022)